{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 122,
  "pageCount": 239,
  "prevPage": 121,
  "nextPage": 123,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses direct quotes to undermine the company's value proposition.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/122",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-122",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "One KOL after another labeled Nevro a “one-trick pony” and pointed to the influx of paresthesia-free waveforms from key competitors as eliminating Nevro’s sole selling point.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b340-d9941ca4091d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "A KOL and former Nevro loyalist stated that doctors are no longer \"as enthralled,\" and that Nevro's differentiation has evaporated as everyone introduced paresthesia-free stimulation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "386bbfb3-afbf-47c2-8ebc-664aa908a051",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "list",
      "text": "A KOL explained that as Abbott and Medtronic caught up, his Nevro usage dropped",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70ec168c-cbb8-4b63-aaca-5dddb0a93b2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "list",
      "text": "A key investigator in Nevro's pivotal trial said the \"sheen if off,\" the story is \"stale,\" and that he \"wouldn't buy stock.\"",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bf76a0f-305a-4a5b-8789-e4d8454a4159",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "One KOL after another labeled Nevro a \"one-trick pony\" and pointed to the influx of paresthesia-free waveforms from key competitors as eliminating Nevro's sole selling point. A former Nevro loyalist stated that \"they were the first kid on the block\" but doctors who \"were enthralled with Nevro are not as enthralled\" now. A key investigator in Nevro's pivotal trial said the \"sheen is off,\" that the story is \"stale,\" and that he wouldn't buy the stock.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7ee257d-8bbc-468e-9eb8-9b58b18b2782",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.08,
        "y": 0.77
      },
      "kind": "quote",
      "text": "\"Abbot's Burst and Medtronic's Intellis are what changed my usage of Nevro the most. It was a big switch for me was when Burst came out. Then Intellis came out and was smaller than anything anyone has ever been by quite a bit. My average patient doesn't' want a big device sticking out of their ass. And Intellis is one charge a week.\" - High volume implanter and KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "066369c7-edc3-46fe-8fe6-dc9d3d4e1b45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.08,
        "y": 0.35
      },
      "kind": "quote",
      "text": "\"Colleagues who were enthralled with Nevro are not as enthralled with it now. They were the first kid on the block. Now it's 4 companies. Abbot doesn't call their device high frequency, just Burst but it ramps up and down. Same with Medtronic. Then Wavewriter from Boston Scientific The uniqueness of paresthesia-free isn't there anymore and that was the main selling point for Nevro, and then you have the bulky battery.\" - KOL, previously a high-volume Nevro user",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c93bbdf-871d-4dd3-97fe-2e0f7786867c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.08,
        "y": 0.58
      },
      "kind": "quote",
      "text": "\"Nevro came out with something new and got a lot of share in a crowded space. I doubt they can hang on to the IP, and it's not the only IP out there. The sheen is off Nevro. I've known [Nevro executive, redacted] for many years. I don't know that he's the right guy. I wouldn't buy stock in Nevro right now. Their story is getting stale.\" - KOL and Nevro trial investigator",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df1d638a-06f1-4d6b-a408-f2b7144823ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Colleagues who were enthralled with Nevro are not as enthralled with it now. They were the first kid on the block. Now it’s 4 companies. Abbot doesn’t call their device high frequency, just Burst but it ramps up and down. Same with Medtronic. Then Wavewriter from Boston Scientific The uniqueness of paresthesia-free isn’t there anymore and that was the main selling point for Nevro, and then you have the bulky battery.” — KOL, previously a high-volume Nevro user; “Nevro came out with something new and got a lot of share in a crowded space. I doubt they can hang on to the IP, and it’s not the only IP out there. The sheen is off Nevro. I’ve known [Nevro executive, redacted] for many years. I don’t know that he’s the right guy. I wouldn’t buy stock in Nevro right now. Their story is getting stale.” — KOL and Nevro trial investigator; “Abbot’s Burst and Medtronic’s Intellis are what changed my usage of Nevro the most. It was a big switch for me was when Burst came out. Then Intellis came out and was smaller than anything anyone has ever been by quite a bit. My average patient doesn’t want a big device sticking out of their ass. And Intellis is one charge a week.” — High volume implanter and KOL",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b340-de80d1a93661",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0b49bd2-4503-4730-b071-d7719c4da823",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "9. Nevro's current predicament - a one-trick pony stuck in a ditch - and drivers of its ongoing growth collapse",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bce2507c-7005-4b0b-bfeb-5ae24e17562d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64d65bbc-e0b3-45e1-9c83-e6727ab165fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}